Importantly, the level and activity of c-Abl can be elevated in human PD in both the substantia nigra and striatum [121], so that the potential of c-Abl inhibitors as a symptomatic and causative treatment is currently under evaluation in a drug repurposing approach [122]. This evidence concerns the gene ABL1 and Parkinson disease.